Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Understanding dementia and Alzheimer’s disease is essential for maintaining a proactive approach to our well-being.

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it, while both treatments ...

DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

“If we get a strong disease-modifying drug and very positive clinical trials, numbers can go back in models and forecasts can be revised upwards quite significantly, quite quickly.” Firms developing ...